News

AbbVie Secures EC Approval for MAVIRET and SKYRIZI

AbbVie has received two European Commission (EC) approvals: MAVIRET has been approved for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged three years and older, while SKYRIZI’s indication has been expanded to include children and adolescents aged six years and older with moderate to severe plaque psoriasis.